Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADA | P00813 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12477821 | 1.00 | PNP (0.53) | PNPCYP3A4MAPTADORA2AADA | |
| SCHEMBL12477825 | 1.00 | PNP (0.53) | PNPCYP3A4MAPTADORA2AADA | |
| SCHEMBL15725657 | 0.88 | ADORA2A (0.41) | PNPCYP3A4MAPTADORA2AADA | |
| SCHEMBL15725655 | 0.88 | PNP (0.53) | PNPCYP3A4MAPTADORA2AADA | |
| SCHEMBL10535912 | 0.88 | PNP (0.53) | PNPCYP3A4MAPTADORA2AADA | |
| SCHEMBL12477755 | 0.86 | NT5E (0.42) | PNPCYP3A4MAPTALDH1A1 | |
| SCHEMBL15728301 | 0.86 | P2RY2 (0.45) | PNPALDH1A1 | |
| SCHEMBL12477759 | 0.86 | P2RY2 (0.45) | PNPALDH1A1 | |
| Phosphoric Acid SCHEMBL12477719 | 0.82 | PNP (0.40) | PNPCYP3A4MAPTALDH1A1 | |
| SCHEMBL15728300 | 0.82 | P2RY2 (0.56) | PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658857-B1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX INC (US) | 2016-11-02 | — | — | EP | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PNP, UMPS, UPP1 | PNP 1/4885CYP3A4 1684/4885MAPT 3498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.